Andras Sumegi

Summary

Publications

  1. ncbi [Mood stabilizers--past, present and future]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház, Pszichiátriai Osztály
    Neuropsychopharmacol Hung 10:31-42. 2008
  2. ncbi [Quetiapin in bipolar disorders]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház, Pszichiátriai Centrum
    Neuropsychopharmacol Hung 10:281-91. 2008
  3. ncbi [Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház ZRT, Pszichiátriai Centrum, Szombathely, Hungary
    Neuropsychopharmacol Hung 12:469-75. 2010
  4. ncbi [Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice]
    Andras Sumegi
    Markusovszky Egyetemi Oktatókórház, Pszichiátriai Centrum, Szombathely, Hungary
    Neuropsychopharmacol Hung 15:105-17. 2013
  5. ncbi [Domino principle--monoamines in bottom-view]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház ZRT, Pszichiátriai Osztály
    Neuropsychopharmacol Hung 10:131-40. 2008
  6. ncbi ["Atypical" antidepressive mechanisms: glutamatergic modulation and neuroplasticity in case of tianeptine]
    Sümegi András
    Vas Megyei Markusovszky Kórház, Pszichiátriai Centrum
    Neuropsychopharmacol Hung 10:305-13. 2008
  7. doi [Neurobiological and pharmacologic aspects of atypical antipsychotic drugs]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház Nonprofit Zrt, Pszichiátriai Centrum, Szombathely
    Orv Hetil 150:1539-44. 2009
  8. ncbi [Application of lamotrigine in bipolar disorder--3T MR spectroscopy follow up (part 1)]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház Nonprofit Zrt, Pszichiátriai Centrum, Hungary
    Neuropsychopharmacol Hung 12:433-41. 2010
  9. ncbi [The dopamin D3 receptor--the gray eminence of pharmacotherapy?]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház, Pszichiátriai Centrum, Hungary
    Neuropsychopharmacol Hung 12:405-11. 2010

Collaborators

Detail Information

Publications9

  1. ncbi [Mood stabilizers--past, present and future]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház, Pszichiátriai Osztály
    Neuropsychopharmacol Hung 10:31-42. 2008
    ..This review provides a wide overview about the four most important mood stabilizers, lithium, carbamazepine, valproate and lamotrigine at the level of their synaptic and intracellular activities...
  2. ncbi [Quetiapin in bipolar disorders]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház, Pszichiátriai Centrum
    Neuropsychopharmacol Hung 10:281-91. 2008
    ..This review tries to organize the actual information on quetiapine's multiplex activity in bipolar disorder...
  3. ncbi [Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház ZRT, Pszichiátriai Centrum, Szombathely, Hungary
    Neuropsychopharmacol Hung 12:469-75. 2010
    ..Agomelatine, a new antidepressive agent may offer new possibilities in the pharmacotherapy of depression, due to its synergistic melatonergic-serotonergic activity...
  4. ncbi [Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice]
    Andras Sumegi
    Markusovszky Egyetemi Oktatókórház, Pszichiátriai Centrum, Szombathely, Hungary
    Neuropsychopharmacol Hung 15:105-17. 2013
    ....
  5. ncbi [Domino principle--monoamines in bottom-view]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház ZRT, Pszichiátriai Osztály
    Neuropsychopharmacol Hung 10:131-40. 2008
    ..The new SNRI antidepressants seem to be more superior and effective in the treatment of major depression and in the prophylaxis of recurrent depressive episodes because of their coexistent noradrenergic activity...
  6. ncbi ["Atypical" antidepressive mechanisms: glutamatergic modulation and neuroplasticity in case of tianeptine]
    Sümegi András
    Vas Megyei Markusovszky Kórház, Pszichiátriai Centrum
    Neuropsychopharmacol Hung 10:305-13. 2008
    ..In this review, effects of tianeptine on neuroplasticity, neuroprotection, neurogenesis, hippocampal stress response, long term potentiation, and, as well as on the glutamatergic system and other neuronal networks are evaluated...
  7. doi [Neurobiological and pharmacologic aspects of atypical antipsychotic drugs]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház Nonprofit Zrt, Pszichiátriai Centrum, Szombathely
    Orv Hetil 150:1539-44. 2009
    ....
  8. ncbi [Application of lamotrigine in bipolar disorder--3T MR spectroscopy follow up (part 1)]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház Nonprofit Zrt, Pszichiátriai Centrum, Hungary
    Neuropsychopharmacol Hung 12:433-41. 2010
    ..Having finished the first MRS investigation, we applied lamotrigine medication. The ongoing second part of the study will show the data of the second MRS scan, after 5 month of lamotrigine therapy...
  9. ncbi [The dopamin D3 receptor--the gray eminence of pharmacotherapy?]
    Andras Sumegi
    Vas Megyei Markusovszky Kórház, Pszichiátriai Centrum, Hungary
    Neuropsychopharmacol Hung 12:405-11. 2010
    ..Cariprazine is a novel agent developed in Hungary, its activity on the dopamine D3 receptor might open up new dimensions in the pharmacotherapy of schizophrenia and affective disorders...